The Oncologist Journal focuses on medical and practice issues of busy oncology, hematology and radiation professionals to aid in better cancer patient care.
Durham, NC, USA
- Tweets 3,243
- Following 316
- Followers 25,894
- Likes 736
Pinned Tweet
Submit to our special series on Clinical Cancer Epidemiology & Real-World Evidence to help advance oncology care across prevention, diagnosis, treatment, and survivorship.
👉Learn more and submit your research:
academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
2
2
1
905
⏰ Last call! Deadline for submissions is tomorrow: October 31: academic.oup.com/oncolo/page…
#Oncology #CallForPapers #RealWorldEvidence #CancerResearch
@susanebates @gbanna74 @PasRescigno
374
🎉 Congratulations to the winner of the 2025 Early Career Investigator Award!
Meet the researcher behind this year's award-winning work: academic.oup.com/oncolo/page…
#Oncology #CancerResearch
1
1
3
682
Heat shock protein inhibition does not improve outcomes in endocrine-resistance ER+ metastatic breast cancer. #BreastCancerAwareness #HSP90
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag4…
2
466
Caregivers are part of the treatment experience. In 122 pts on 2nd-line therapy for metastatic breast cancer, caregiver fatigue & QoL tracked w/ pt distress over 6 mo of ePROM collection. #BreastCancerAwareness
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
1
3
494
📣Oxford University Press invites applications for the position of Deputy Editor for The Oncologist.
Applications are due Saturday, October 31, 2026.
Find the job description and application instructions here: academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
4
4
910
⏰Just one week left to submit to our special series!
Submit by October 31st: academic.oup.com/oncolo/page…
#Oncology #CallForPapers #RealWorldEvidence #CancerResearch
@susanebates @gbanna74 @PasRescigno
1
4
614
Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer
#BreastCancerAwareness #sleep #fatigue
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
1
3
529
Comparative safety of concurrent adjuvant trastuzumab emtansine versus trastuzumab with radiotherapy in HER2-positive early breast cancer
#BreastCancerAwareness #radiotherapy #toxicity
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
1
4
6
871
A View from the Periphery: Trial Design, Commercial Competition, and the Access Gap in Multiple Myeloma
@susanebates @gbanna74 @PasRescigno @drMehmetbaysal
doi.org/10.1093/oncolo/oyag3…
1
2
651
There’s still time!
The Oncologist is calling for manuscripts to be included in this special series. Submission deadline: Oct 31, 2026.
📑Submit your manuscript today: academic.oup.com/oncolo/page…
@susanebates @gbanna74 @PasRescigno
2
4
568
This small pilot trial suggests #cannabis may improve symptoms in #pancsm w/ ≥10 mg/day #THC 🌿 linked to ⬆️symptom improvement. Higher #THC doses also correlated w/ reduced #anxiety & #insomnia. #PallOnc #SuppOnc
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
2
3
536
International survey highlights that drug–drug interactions remain a major challenge in #ProstateCancer care. #MeetURO #ONCOassist
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
1
2
554
Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag1…
1
6
12
1,095
📢 REMINDER: only a few weeks left to submit to our special series (submission deadline: 10/31/2026)
👉academic.oup.com/oncolo/page…
#Oncology #CallForPapers #RealWorldEvidence
@susanebates @gbanna74 @PasRescigno
2
4
1,132
This retrospective analysis showed that #nilotinib provided an effective and well-tolerated alternative after severe #imatinib toxicity, particularly in KIT exon 11–mutant #GIST, but lacked activity against exon 9.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
3
4
6
1,006
Real-world #US 🇺🇸 data show #IO + #FOLFOX #CAPOX was the most common first-line therapy and improved #OS vs chemotherapy alone, driven by PD-L1 #CPS ≥1. Outcomes remained poor and more studies are needed.
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
1
7
21
7,178
A small #Japan 🇯🇵 Ph2 study suggests #goshajinkigan, a native herb, may reduce grade ≥2 paclitaxel neuropathy 🔥⚡️, but results were less certain after stratification. Larger, blinded phase III trials are needed
@susanebates @gbanna74 @PasRescigno
doi.org/10.1093/oncolo/oyag3…
1
3
925
Oxford University Press invites applications for the position of Deputy Editor for The Oncologist.
For more information: academic.oup.com/oncolo/page…
Applications are due October 31st.
@susanebates @gbanna74 @PasRescigno
1
5
5
1,069
🧬Combination ICI outcomes in heavily pretreated advanced sarcoma: although many patients had rapid progression, durable responses were seen in carefully selected patients, including those with ultra-rare histologies. @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo/oyag3…
1
1
5
1,497